797 results on '"Gurnari, Carmelo"'
Search Results
2. Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation
3. Hemolytic versus malproductive anemia in large granular lymphocytic leukemia
4. Clonal hematopoiesis–derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders
5. Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis
6. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
7. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
8. Diagnostic evaluation in bone marrow failure disorders: what have we learnt to help inform the transplant decision in 2024 and beyond?
9. Myelodysplastic Neoplasms/Syndromes (MDS)
10. Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations
11. Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting
12. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
13. Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study
14. Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
15. Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms
16. Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?
17. Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis
18. Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature
19. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia
20. Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry
21. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia
22. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia
23. Molecular patterns identify distinct subclasses of myeloid neoplasia
24. Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
25. New approaches to idiopathic neutropenia in the era of clonal hematopoiesis
26. A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS
27. How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
28. Molecular landscape of immune pressure and escape in aplastic anemia
29. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT
30. When to use which molecular prognostic scoring system in the management of patients with MDS?
31. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
32. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting
33. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia
34. Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT
35. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
36. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M
37. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
38. From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers
39. A multimodal analysis of genomic and RNA splicing features in myeloid malignancies
40. Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms
41. Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
42. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
43. Thrombocytosis and megakaryocyte changes associated with PRCA
44. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia
45. Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia
46. Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes
47. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms
48. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
49. Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations
50. Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.